Exchange: NASDAQ·Updated 07:30 PM EST
TYRA logo

TYRA Tyra Biosciences Inc

$20.29
$0.39
(1.98%)
Today
Closed $20.12
$0.17
(0.84%)
After Hours
Reported EarningsNov 10
Mkt Cap$1.39B
Vol467,582.00

About TYRA

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
43

Bearish Sentiment

How do you feel about TYRA?

Mjust
$TYRA strong cash position, but a few things worth examining. TYRA reported approximately $700.5M in cash and marketable securities after raising $400M in September. What caught my attention: • All 9.08M pre-funded warrants issued in the September financing went to an existing shareholder affiliated with a board member. • Q3 R&D expenses increased approximately 69% year over year, from $25.5M to $43.1M. • The company still faces significant clinical execution risk, with its valuation dependent on future trial results. The cash runway looks strong, but cash alone doesn’t guarantee clinical or commercial success. Interested in how management balances spending, shareholder dilution, and clinical milestones.

Advertisement|Remove ads.